This section includes information and resources about Diabetes for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting
CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union
Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus®- For Non-U.S. and Non-UK Media